Epilepsy and Seizure Medication
  Novartis Pharma US

 





MONOTHERAPY is a realistic goal - See results from a study showing that more patients achieved seizure control with their first antiepileptic drug monotherapy than with their second monotherapy. Go

Novartis Medicare Resource Center

Patient Assistance Program - visit www.pap.novartis.com

Pediatric Efficacy

For pediatric patients aged 4 to 17 years,
the goal is first-line monotherapy control

The first and only newer antiepileptic drug approved for both monotherapy in patients 4 years and older, and adjunctive therapy in patients 2 years and older

TRILEPTAL provides a strong foundation for partial seizure control in pediatric patients newly diagnosed with epilepsy

Reduction in frequency of partial seizures1,2

Boy with ice cream
Adult Efficacy
Pediatric Efficacy
First-line Use
TRILEPTAL vs CBZ
Graph - Reduction in partial seizure frequency over 48 weeks
Multicenter, randomized, double-blind, controlled clinical trial of 193 children aged 5 to 17 years (n=62 intent-to-treat TRILEPTAL patients experiencing partial seizures)—48-week, double-blind maintenance phase. Median number of partial seizures per 28 days at baseline was 3.0 for patients in the TRILEPTAL-treated group. Results achieved with a mean TRILEPTAL dosage of 20.2 mg/kg/day (range of 7.8 to 38.9 mg/kg/day).1,2

Well tolerated control in a young patient population (patients 4 to 17 years)

A low discontinuation rate (2.1%) due to AEs was observed1
No discontinuations due to the following side effects2:

— Aggression
— Psychomotor hyperactivity
— Fatigue
— Cognitive AEs

NEXT: See studies of adjunctive therapy

References:
1. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazapine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205-213.



E-mail this page  | Print this page




TRILEPTAL Home  |  Professionals Main Page  |  Efficacy
Safety and Tolerability  |  Dosing  |  Resource Center
Important Safety Information  |  Prescribing Information

Site Guide  |  Contact Us  |  Sitemap

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008 Novartis Pharmaceuticals Corporation. All rights reserved.